lgnd-20200406

0000886163-20-000037.txt : 20200406 0000886163-20-000037.hdr.sgml : 20200406 20200406171503 ACCESSION NUMBER: 0000886163-20-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200406 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events FILED AS OF DATE: 20200406 DATE AS OF CHANGE: 20200406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 20777727 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 lgnd-20200406.htm 8-K lgnd-20200406

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 6, 2020

LIGAND PHARMACEUTICALS INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)


Delaware	001-33093	77-0160744
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
incorporation or organization)		Identification No.)


3911 Sorrento Valley Boulevard, Suite 110
San Diego
CA						92121
(Address of principal executive offices)						(Zip Code)

(858) 550-7500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	LGND	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 6, 2020, Ligand Pharmaceuticals Incorporated (the “Company”) disclosed that its estimated cash and cash equivalents were approximately $735 million and the outstanding principal amount of its 0.75% convertible senior notes due 2023 (the “2023 Notes”) was approximately $516 million, in each case, as of March 31, 2020. These amounts are unaudited and preliminary, and are subject to completion of financial closing procedures. As a result, these amounts may differ from the amounts that will be reflected in Ligand’s financial statements as of and for the quarter ended March 31, 2020.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On April 6, 2020, the Company announced that it had repurchased approximately $234.4 million in principal of the 2023 Notes for approximately $203.8 million in cash, including accrued interest of $0.6 million, during the quarter ended March 31, 2020. After the repurchases, approximately $516 million in principal amount of the 2023 Notes remain outstanding. The Company may continue to use cash on hand to repurchase additional 2023 Notes through open-market transactions, including by entering into a Rule 10b5-1 trading plan to facilitate open-market repurchases, or otherwise, from time to time. The timing and amount of repurchase transactions will be determined by the Company’s management based on its evaluation of market conditions, trading price of the 2023 Notes, legal requirements and other factors.

In connection with the repurchases of 2023 Notes repurchased during the quarter ended March 31, 2020, the Company expects to enter into amendments to the bond hedge transaction confirmations entered into in connection with the issuance of the 2023 Notes to provide for the options thereunder corresponding to such repurchased 2023 Notes to remain outstanding notwithstanding such repurchase.

The Company also announced on April 6, 2020, that it had repurchased approximately 473,000 shares of its common stock for approximately $37 million pursuant to its previously announced $500 million stock repurchase program. As of March 31, 2020, the authorized amount remaining under the share repurchase program was approximately $253.5 million.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			LIGAND PHARMACEUTICALS INCORPORATED

Date: April 6, 2020			By: /s/ Charles S. Berkman Name: Charles S. Berkman Title: Senior Vice President, General Counsel and Secretary

EX-101.SCH 2 lgnd-20200406.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 lgnd-20200406_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 lgnd-20200406_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 lgnd-20200406_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover page. Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Central Index Key Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 6 lgnd-20200406_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Apr. 06, 2020
Cover [Abstract]
Entity Central Index Key	0000886163
Amendment Flag	false
Document Type	8-K
Document Period End Date	Apr. 06, 2020
Entity Registrant Name	LIGAND PHARMACEUTICALS INC
Entity Incorporation, State or Country Code	DE
Entity File Number	001-33093
Entity Tax Identification Number	77-0160744
Entity Address, Address Line One	3911 Sorrento Valley Boulevard, Suite 110
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	550-7500
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	LGND
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.ligand.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lgnd-20200406.htm lgnd-20200406.xsd lgnd-20200406_cal.xml lgnd-20200406_def.xml lgnd-20200406_lab.xml lgnd-20200406_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lgnd-20200406.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "lgnd-20200406_cal.xml" ] }, "definitionLink": { "local": [ "lgnd-20200406_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "lgnd-20200406.htm" ] }, "labelLink": { "local": [ "lgnd-20200406_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lgnd-20200406_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lgnd-20200406.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lgnd", "nsuri": "http://www.ligand.com/20200406", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lgnd-20200406.htm", "contextRef": "iac11ce4a6d124a5fa1a77a8c3b3a7077_D20200406-20200406", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.ligand.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lgnd-20200406.htm", "contextRef": "iac11ce4a6d124a5fa1a77a8c3b3a7077_D20200406-20200406", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ligand.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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lgnd-20200406_htm.xml IDEA: XBRL DOCUMENT 0000886163 2020-04-06 2020-04-06 0000886163 false 8-K 2020-04-06 LIGAND PHARMACEUTICALS INC DE 001-33093 77-0160744 3911 Sorrento Valley Boulevard, Suite 110 San Diego CA 92121 858 550-7500 false false false false Common Stock, par value $0.001 per share LGND NASDAQ false ZIP 13 0000886163-20-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000886163-20-000037-xbrl.zip M4$L#!!0 ( .&)AE!HF3OS+A< '"< 1 ;&=N9"TR,#(P,#0P-BYH M=&WM/6M7XLBVW^=7U&7FG&.O92!/DF"W9S%".\Q(:!5U$NKDJI , ].$A3\ M]7=7)>&AHMC3MJ*R5K>$U&OOVN_:5?7YOY/ 1U9R\:36.O M/TB1+,KBK9=QC=J&YKJF+(B&X0BJ1$W!UC194$3JJ)JJ&)KC;/=KCN28U-6I M@"F5!)68HH"QZPBV;FJF[E+9M>UM4M,=R=!DQ954651UV35=6C6Q*%9%Q]%= MPV3=#E* #B ,D]HD\;Z4!FDZJE4JU]?7Y6NE',7]BBR*4N7O]L&Q,Z !%KPP M27'HT%)>B]!YK8D=^^6$.N5^=%6!%U!7,@51$A2I*.Y-EOK@-;)>)*7BA;X7 M4H;7>?'T_O+SHI4TQF'B1G& 4Y@BUI(FB+(@5XM&6"5O5;OI12.DDK?,"5W5]^^>5SZJ4^W?7[ M(1$8E8JJ6/U%H+HY -P)O46$$: M9U\]0FC(O$["Q@F]IRL_TEZ1-TO)0\[DN10%5>))*M8<[&$=1T;CF(K6!=U M_:)1#&4VIA(*<<"ZIEZM&<+XIGL 3HS]5DCHY"\Z+2&/0--$.9W:C>CJ0#ZZ MZBGM,1DVK\[WS6%G2(;M;E]J#ZV@W3V?!B=PY:UZW&[WKGMQ6 MSH=][4"Q_-Y-I/1NFJK5;=V<#YMB>U@7K9L_@\[9N6\-_4&[49?;^];0DGMJ MY]00#^3S:>_,J?:"HX'5/9F>!\VI%4#]QJ%\OM^"?BRH-NMCK%G5. MH2\M/.^.@EZW?]TYZTVML_:D<]82>S<#*$^\]M"!OHX\J_'ULMV ,9T:TX-N M,VT?BY.#;OW")(;J."X@6*<@?*H.2!7#,02J54'\4)5062KMBO QC*I453Y7 MEN;S.:>W#B*6,#'[UR\DJHX'O(:NB(C1&?$#T7FF]U_IKF0-N5]XM?EIN?03HC$CQ!-HF3AM@+>RR00FB M*C !>_O=;)AD1='B3?%<=%)90E2!U1D:*PNRN0(2/!/C')V/&0P74FFQ3B[Z M!Y09-#5='J4[UQY)!S5)%/^U4^*%=C\G(PS48\<5J)I]SUJXTPX;K8!]KQ_6 M'$ ?C5D3K$91P,;.93^.QD!)3N1'<2WNVUNRIFT7_Y!8%C_M9.]^%?EGQP4T M""X./']:^T_7"VB"+'J-CJ( A__93D#E@FZ./3&DL#BL;I]9"M(Y6!6]H'5C-1RP/EH3"]IO M-_J3WA#J=/M:>]@'Z^%4)7_\Z9_+_I4]C*1.@UD*IWZO>^3UAFW>7P_ZMH;U MZT[CJ]>6VU#FW2 MKB'\==MD0!M 86^7=^3UX +Y?M2TNNBH^:USU'T[<'T;Q\D8ARE*(W1,'>9& M(TE!48PD;8M\0I&+T@%]._ "C./82SUHLCEQ!CCL4U1W4@:G9"KJ$P -<-SW M0B&-1C4F?U^,,]>#FYF]#,@C.HKB%&T5SQ2#X4N3%-$K%I*+^6M*/M5^O*+( MXC10>Y+6"'0?0(L#@J=3& ,-[U,DW[AYWLR,]O>E4:8PK@O9(*+I*JK@2"R\ M(#D&^*&J+JBNH5")Z(HC.J7=^BCV?%3=YO'1?Z)<%BB:LU/^;$=I&@4U_06) M?$T#Y]FC94>T[R4LZ)A:\.;=463OPG8DEYJR+:@ZT025$E,PM2H65$)@M<_U5S\X1BUK[S9Y=HY G8(OV"C(]%7(4/5^ M\D+L?7F;,QF-#EGD\8:LYP:#=&+5FTK^@7X03=#RB#@O!$.2%J)4F:&^ M0?C'GYXN,W(9D2O"%-L^+>KD)7SJIC4\3J.B"E_3R7ZQHYC0F"',QZ.$UHHO M.PO]L?K9LQ>RV%&-35H10L^6! 3>;QY0,:IE33&X5$AC^$>*\>3QEG(6;ZFD MY.Y+12HKBK+Z_8.57[)E= M\UEF/ZU)YW<)YHK&J>=@/_\U\ B!.2MZX%0BEV7F;12_980BW54_CUA!:W/5 M,C.N"=DS:)L% XDM?K' 9DI'<73%U-"RA92IHU;H1#$8;'SUZYB5WH-QI_%T M+R*;J9VRF+\5G%Y:@K5L.',I?PO:U99VVQT_A]V#ZS+D$SW8KY M1_+YV:'2ZYX.K9M+*.>(G3/08-U+L7US">T=JNW]]J0G'[(Q7A]TZ[.8/]:Q M0QU)%;!H@JUE*HY@8DH%5R149@%>5]+!C*8^O@9S]6[8/Y>8.>N]+%-E37XP MU7TFW%?/I]"Z3>,/!EF#0>:+8AI19<=A*RJB!O:?:Q/!K()OHAB8B+9N2HIM MLY4>25 4T;R[U/FJ..1#[:SFD"Z>M/+5.8=KE@]V69M=6C-VL4U%%=5J50": M4,!WQXI@$YT*5:)BD6##D$Q"ITY MS\Y)6]QD8K'.*!W0& W'L9<0+PN"1N[KDE@_1J>_$L3O14'@)2P]$#%]C#() M\^EU8?Q-D7JK?%0^+J-F,/*C*8T_I,NSH]Q;=,ZXD(G[./1N^/,ZI/YTI/(8 MR1IR0UJ%SP_&^]%4L&Q)(2LJ?[K+>Q4>N'IJC%YY*$1_7_K09@;R)!%0F6=' M/3F2IU;+NJ1_9TA-+$NK7P)!B@\$\AZL^]B0#6/=*.!;$]UOTZ.J$Q+3),G_ M' "%2QOL3?6&@Z G'P76L*5:^RP+MR^V]UOB^?!2:@?6Y?G9D=\>GJCGP_;M MC%ROLW\^/-^'D0_[8F\(WE3C\+HW/ HZW9,IM.F?[Y],K>X@:$O+T3EJZX1@ M@H6JI#B"*AJNP#PH090E1U8U33&J[,'73MR-KL,/:?.8M)DL2INJ:A+) M)%305-<65)MJ@J$[BF"8CB$3N6KHBE[:/0:":GBT'WU(DP]I\O:E"0^6=>)O M<73E\9U_'R+E89$R710IQ% T!]M@NZBV*JBZ;@A8[5 M-UZ6?##M:V+:;U&28O_<&VUX1L#/8]GY"HX"3@<6%460;(EM&:=$L!W)$3!V M;!O+&IN=TJXI2[+TL7CS\R/:.86SM+91#!K)&V$?T0EUQJEWQ;+=7,^AR4>@ M];W0 P@YQ*3<#XNO2MIK3NM7>:[?UC,J$N8^UF.*-U9U?'>J\TW[YO!"8Z=X MZ$029 W+@EHEX 2:$IAMCFLZKEBE&I5*NX9FW!;^G_[]JU05=YYQ9@XBX.%O M@RCOR4Y MGXH5Y15A9<7>$*M2?].3_C6*@;;S3/\8Y8^YD;2-/)=E]X=]2M Q<]_1 4[2 M?#?84^;]X>7%UXVCO0%U+MEV1H1'HS@"JY&E_]C1!-G4CZX9CMA+ACID"'\A MU_,9?W@)\MBQ/^ L%V2B1>,_12'-!HG_A0E./42=\IKYA4B&S"6+_MG3<;S M?1> #9@7'$Z+=V[D0^>L'DOU]EA23%);@=EU5G7S555!ELN+AEQFW*EE_5FL MFCK@TD> '$'MXU4S)3TV4YE9\^RI]784^38&Q*Y?7-RH58Q)J:D"3)+6E2K-F'6CRI0172IK4JJIH+U\^]?35U5 M=U:YOZ]3&&0DEAEI^70#A2W.-QHM[(H^&OLT*ZS*6LZ^C&\7=A*S#<1;DH[V MOAXA61'+4/ 1F?K!I/^$28\C\"@!]6&_#1*<0?6^.%1I#P\OL$9LJAM8L%7= M$51=(H))@5=%:CJF+HN.;-(WP*'SN49!/MDKV%-2L2#)"QRZM,%_QI^J6,Y* M?K#H,[+HMY@R'-'PC#S*>ZX[GMS5E6 X4*J4EU4#%O0"6&AA"H6L*'8 M@E1UJ2-KIDL4Y0VP*LRYX"Q,^GI:55*)(&_9G]9CW*SL!^O^/-9M)18G'>JO%U,=L)6?Q@,3%D'+&;_#^+YBDR? M"G9,\:6 73!!:MB_QM.D5/FA9SJ^5@+)#I)8\':R8 :-*5DBB-GI45R8Y\&- MNO.BU/^HK,V 2_])O&4SLNA-HVSHWWL<1K5LF-^;1/_P2[.LF,]S'(9>UJ7- MRZ+/%Y%S"N"KD*,4@43S")HMB68OBP7F6V_76W]>,Q5&_0FI,%UV2GIV%)DS M0(Z/D^1U[0-\CW,28[XT=#P-[,C?6BN+8K-G)"\^FY 5Y5_KA!4'/'$>HH7U M!=KX>N#!+W.5_4HSDYXPHWGO;YX'GS%_(#?FII)L<^F[D1Y=EAC8#IK3\V[S MYGS_*+!N^J+5.)RT;P;>>:,NM<]ZOR?+^G M=!J'4+=YT]G_\[+=.)F<#UF=GF(-+Z?6Z?+V $53JKJLL2U(5? &%0.\ X7J M M%MV91$4Y=44MIE/C0PX'$:.9?;:(1C=(7],46_L>V,$AJQ8_,'FW*4T =C M_A3&S/5NIG8_N'(-KIR?3V03B52!+P4B&VS3CFX+MJ9* B6VHLFN4Z6B7MH] MV+<:'QSWMHR?9P^5,H/J[AE\A18M@ET;>R3LS^;9>8J]:F"QJIB*8!):%50L M$0%775'051,;V)9LQ01-VAU09.&$X/^A?3^RL8_:.+ZDZ>-9]P\G_CYAF6## M\IVRL%8K)"QT2Y$]10[/?0H ;^ 24'[ 7*<#%@$> ML60EG"!"7>B#'Q;+@K](%;4BS'SB&#% -M(505#4D1!)A(V MJ>J8CFELZ/I51FFKCN7>2*9ON0](XFV0O_>*=>].JND A#;UJL$+DV8Y0-(2M1G*_Q;LR@ M5S'VFO?NZ??=N_=N%Y>+=IC6%(#Y8^RDM60<@.28OIJM#7=V;D@:%X@"PIX"GA%!R<#3AC\"[_+&?O@["7HFL;Y_H\) M+^M/T6^ZHB$ VF?*B55BO4;CE*NS;&-&L;\8!TS7,0)D_8G@(_Z+F;4\A,,7 M^6GH@98$;0NX(V/*8%66P. _6.S]#))KT-.W1J1)U6)$3.'G:Z,XH=O,$X/N MP0.&7Q0IPV89@8\,JCT;'K0&,(Y#/ 9. &0PD$8@\;P N"0&"X+]P(HD8WL( M.IGI9J[Q:;%G9:[=&8KSO2D.)>.8)F54AP[ $&"\N,UPM=!Q@*S'B'Q3^\<';-.<,8]WCG@C$9@!/$;3Q +:& ,E+0F^OYE.2D MQE$'%AGH,\K1.;/(C#7=;TY^.. HWUZBZ\72,\H.HS@?F[6C('&<#Z\)]+8=POV!RHNIQM)\BO:I[ABPSJG6:,L2JC# M@U!-=NU$2L+0QBJ,]=,X(D1=K7>&$049AKKEK27%;6L MSC00T-E1L.=<:G(=OUQ>5LK%8GVD]IC>*+;[@H\5CSG@L"2#A#/2;6%[0 M,2#:6<%'Y2JJ,R,U]S0+@)+M!_37,CQS!7H+K)@&&$HNJ%WP!KL+6&6JA460 MO!#4:N[* L@,E<1ZN%&U-D%BUS#CP@4[AK8L=$ O9B?(+K2]AJ3AJ_MIC MFCS3D$"8K#K[R]4X^\;GC"GI&;86(%L<[TR?$@HC#7A\UIXN4N-,JP+5@ZO! MTWIM3H1L:IC1Q):E9[M5\U$[A14-@YX!&GL.O3MSV\BG??(0R2V&8&A:(NXY[Z_):;CXD60N9-(BXM+@'%B]A89O[YIMU ME8=W9J98-,I:9C-.,ZWML&-8DU&46=!LW_28)R+-$;'V8=19EDE2^"Q.EI:2L+24^W2)HL\$]V+L MCE4=L>!?MNM]/KK?-.BBJ)&UNB"KH.E^C /N,]SQ6C(2Q^-T$,6 JYFXRTAA MV0#D0-S3\GW.DZPIY9E#5[[WTL;OLJD>L<^^N^*/M C7B1$\UW#NOQ'YN;#V M[F-YC^T^>%%WX-'X5[ZMI+5OU;LG1\WCM7;T*8RN'N5967Q%?M"*N/;BO>N9 M[;!@/7V/+W[/V@\9@S1T\#B+D7E)?KLWZQ(LQ@00.+<";0H.L5O8CESNY@4R ME0YU>'-S:7U7_=Y.ELKRBXP[UU2\IFTQ6MG,-Z \_6X)H!C]NW>^//12@U$I M/VCSRCLXW/"^ 4,'&WDP[.JKL^]*POC1XZ43Q.A3GZ_6BTS65@Q **25/A=]CYT=UQ&O]/X$OI#Q6>] MPR/>W]RS!&8V^_?@[@-E]Z.,;Y_B.#O.5GY/68ST6TP3CZ%D&^W3D,8\+6$< M)M3G@5&PZV.:XGAZBQ+7R%M>P)?YM/C"H@>U^3YWQ8[(%/X,TL#?_7]02P,$ M% @ X8F&4'F=!1*C @ "PH !$ !L9VYD+3(P,C P-# V+GAS9-U6 M76^;,!1]SZ_P>)[#1Y(UH":5UJK2I.Q#7:OV;3+F0JR"S6S3I/^^QH$E),TR MICULDY PU_<.Q#B./)), C#^AX,AY-)Y2^S2+JTQ#2,\ $ MP,?C)/0P(2G%\5DX"<]2"-(XMJ1K%2FZA((@(XRK:*UFSE+K,G+=U6HU7(V& M0F9NX'F^^_!Q\=6Z.HUOSOACQWL=R[SU'[GU=$P4_'#/>-)QSUE&>#*DHG!K ML=[8>^<@HK5D<:7A6LCB"E)2Y7KF5/Q[17*6,DA,PG.H4]IQV)G61&:@/Y$" M5$DHG%QR/D"HS@,K2B$UX@? E*C8RJH4S@@I#=0/L>?CD>^@3?86@A)M2Z+! MV%2\"G0AUZJUX"W5<*T2QST9S,ZN^&$8NNLZS4?#.-P5ZX_K(?:#?LMVB1A7 MFG *?=8V7[C%_8D8MB76+X86US\&2Z: #C/QY"; 3M:".@:J!T>WGW NM&6I M+8VM+!E/Q<9@3+6(J%5R VG;P0=M^4JYV%=$))4B/U%;;BE%"5(S4+LM;0F6 M$M*94SMHU$%KE5NYBJZ=ET,^E85!F2W+89.AO MEI] VE>^@3#._@OU.8G[JC<0R/]YX:6$OL(-1)EK['?*OL;?FGG$S(UZ*2F?AJ^]W-AV-7GEUVZ]YRMJS;.IQ[YL(W#\+;'QB,+!+5T'-W'[!'52E( M/O.Y'>_K;,"-RT^ >\?"+^.Z_?0JK#&V>6P.6;=[RFZ^=TYB:]@<\O/!"U!+ M P04 " #AB890\]C8$(,! #. @ %0 &QG;F0M,C R,# T,#9?8V%L M+GAM;)V2VV[;, R&[_,4FG<[6;)C-Y81IT!3#!B0 4.ZHKV59D!WP(#=2"#YD3]):7LY#3UZ!.N4T564Q#1"H(5IE&ZKZ/;[9UQ$E[O5 M:OL!X_NKXP%=&_$P@/9H;X%[:-"H?(?N&G G)*T9T)VQ)_7(,=XM27MS?K*J M[3Q*:4I_C=H2ZB*7DJ68%H7 60(,UWF>XC4%D>79NLB%^-26(A$,Y 8P!TAP MUC"*.9<"UQN6LXV$5-;U4K17^E2&H^8.T#R<=HM919WWYY*0<1SCJ;9];&Q+ M4DK7Y(6.GO'I-WY<+W3"&"-+]!5UZD_@7#8A]U\/-Z*#@6.EG>=:! &G2KZP>%5:48O@N3'MV3R MIBYX+Q[Z9=C#;#^7"&+_TPA,'G0#35#8DG>OO5O] %!+ P04 " #AB890 M(4:OT"$" "2!@ %0 &QG;F0M,C R,# T,#9?9&5F+GAM;*V476O;,!2& M[_,K-.]VBB1_U'9(4EC'8)#!R%;:NZ&/(T?$EH.L-NF_G^PF_4I+8 M\YY'1^9,SW=-C6[!=::ULXB-:83 RE896\VBRS_?<1&=ST>CZ2>,K[\N%^A; M*V\:L!Y=.. >%-H:OT)7"KHUTJYMT%7KUN:68SP?DB[:S9TSUWE MNR/]-AG4K"Q+,D0?I)UY31AL&;G^N?@M5]!P;&SGN96/!4)YY1\2G])DY#X8 MI)V9=$/^HI7<#\_S[A70FXI^AP\RW!]A%KK,QKM.1?,10O>=XTZZMH8E:+1? M7BY_'),:ZXDR#=EK"*_K0#PX^+L-S*+.-)L:#FZBLQ_GU/R'QL?=)>=N&FU,V^,CZ!+2# M$6Z@$>!.B?K,]PGG ?(E86]9FXI;-99M0P:XBS9,X5^\@O?!ZLHJW(]3FM*S M@> Q^4GU\,S&FGYR+,)V[]#7^A\.V'FP"E2$C)I%AIT!Q&'J9HF@*2\TI[)( M6094::Y$GOQ5O$SS@B4XUDF8ZS1F6#"E,:>Z%#$4/,^3'G9*GDWL^>@?4$L# M!!0 ( .&)AE"@\K&^@PH ,Y> 5 ;&=N9"TR,#(P,#0P-E]L86(N M>&ULS5Q=;]LZ$GWOK]#FONP"92Q2I$06;2ZZN>VBV-RV:%/T8A<+@U]RA-I2 M("M-\N^7E.W$LB6;DFS5+ZUBCX9GCG5F.!*IU[\_S*;>3YW/DRQ]'YF\F^FT\"YSS0NMO/NDN/&^ M*SW_X<5Y-O.^9_F/Y"<'X*(\Z3*[?>Q!")BA$6Q1K$0I=-IDOYX M9?\1?*X]$UPZ+_]\O1J/[^_OS!Y%/S[-\,D*^'XQ6UF=+\XO)J7'UYEDA8T6]B^P,@/V(P -=?#\8:[.+EYXWH*./)OJ+SKV[/_?OGQH')*-K,4HU1/[ MRW[6>9*IKP7/BRLN]-2@+[T5C[?ZS=D\F=U.]>JSFUS']6ZG>5[Q:E$RBQ*& M%N5O38.->L _$-YB&^L!P)7A?CP4QEVK-F3D:*YV,O^=)80POL]GL+DT6F7L^#C'3,.*A+4JF=ODZ!%2J M"#"E L94&&/%Q\7313W6*?CV=35^.$8&#:B< "^<42I%=%^7KT'% 7&J?')V=Z4KQDLH)D:J<" M6;X9>R;WQ_ZLK;F!708^U_)\DOT;XVR$-,.>>5FN=&YFL#4A5*[!S[FV MOLPD5]MY[+65?_XICG4^IB&2/.8($!_% $>$ 3,Y#8 ?!B0** XAU*YZ;A[F MU$1MD *Y!M5;8/5*L.[:WL'K?H$?AJTCJ[P;4:W$OI^''HK?X7PPV>\/<%W[ M#M;M$\"[M$B*QP^FRTODGH7NGB!<>-^?*0[, MYI%3QB&(;)5 6M#3(Y.XC#)82FD1\GIN:7-:UR3S5BES-&G_#J[3$\Z5FD]N*W6-MFCVU" M73-&+YJ&R1+M&.J0%AHYZ)T*MCT/+/_&T+8EWVS:7N9?LVDBDR)))W^:U)$G M?#H.@B#F =< :8P!%E "CC@!@D=8*4FX^<15X=ON3TWPMU_. M_3@YLI+;T-%*P,U1]]!NC=/!9-L(V5NM:X0ZW6\BXW7M\]R!OSZ^J/YA*Z)("07/93YV_%O,BY+,8^CV4 "0>84]/5@6-KK@S^ORMD_SN0ZNJB M[2.[BK_A=%<71D5XM09=V]5K_O!!:7,8+Y]]?[R;"9V/HR@@$$R>,+=;V7TG=$T/[Y.I?LH(?J1Y) &C& (L[5,E[H<@ MCB,,WEP*+= M#F9;IS4V[:6YVB-Q;4X=2Q9CC(( *!B;-I7[$E $!8@0)X(B#1%S7B2Z[OC4 M)/FT,<2"7V>R6IX_CR"?<5\KH6=H]%R'V 4-< \(D]@/$*87.Y73' M."EJL.DM_)1&_AUWL?6/X[0]Q. KO- MNS^TA4A<)\54CXED2%/-S"0Z0D;_/ )G\U$1?@O*R MV(/H[^(?W@IN^Z>U3^SMEW@?3HZLZ[9T='I,NQGW 1[1/KD<_/'L9C!UCV:W M;-J+U.YEGWZ^R=+5'149:1FBF **,0&88@:$XK$YDM*H-,*A=-X^L>G\U$1: MXO-*@*UO16T1MU^??>@XLCY;,-%*FDTA]Y#FELO!I-D4S+HT&VUZKGDL]S=\ MRC_GV<_$ !U#*&)!* 8!LLL>8ZD )P("*0F7*" $2=9IV>/&0*WD_Y9!S@0&N3 "CU+36T!#'5&A:ZRCP-:281,)Y6U+%\ZE)_PF< M9]&YZ[Q*UWYA=R;AR$IVC+^5;&MC[:'3JK_!A%D;QKH2ZPUZUN3/V;S@T_\D MM^4RO1 J22+?!Z:Y-169,@THUSX@2 E. JFX>W?;/,RIB7*SO"S >@9MIRW& MM+#O!1HF^K]2CXD@4<6=R_N M^KPGJ)&4P[TM:'N(7_7.H,9@=[PYJ/F<[JN[GE[[^(?IR<=$^(%OWQ@4*"( M#GT,*(PHT 33,):$1D'K95Z5$4XM43PM>5J@] Q,S^)LO_2K2N3^C-";GB.G M@=;,=%H75AO] 1:(5?T.OE*L-JRZ)6/UAEV[\2]ZDM@=&VE1[FA%@E!EGUTQ M'P< !XP!P93ABQ,2!8I*X;XMN&Z 4Q/SLJU\!MER6W MB:XM=W=JAFFV75GI MT&/7A]Z[N]YP.W!?71_4=D?=8-K\S1Q8O5)\GB!>@7+_X/4$L#!!0 M ( .&)AE"@#]EOLP8 &XQ 5 ;&=N9"TR,#(P,#0P-E]P&UL MU9I=;]RV$H;O_2NVV]O22U(D11JQ"]=-"N.XC9&X2-&;!3^&NT*TDD')L?WO MSTBVFVSLI,):@%7#V ^)TLR\\RPU'.G5SS>;&<[=/Y#"I?AZ): M'<[_O'A#]/SGH[V]5S\0\M+Q?7U]?Z-2^5^G58+3FFV>!@]OQ]^\VC\==:/9L:81;_WGZ%- M\=1 /"U;_/7[V7N_AHTE1=6TMO*=@:8X:/J-9[6W;:_YO_HU^^:([AMY&$:Z M382A=&S_I@GSH[W9[$Z.5)?P#N*L>__SW>F6R;)8V2KL^WJSZ'8O3FJ$X=RN M.F?[@]O;2SB<-\7FLOQGVSI!/)R7JRJ0+JM44-69_/'SP8O/UB\3- A,'^T9 M;K@_1V=M%T_@IH4JP%U\#S;*VF\-*CMUZ_1P9&D=E/W698!BV9_YV#5MLKY= M"@@R@) D#P()C!&(RS))HJ=!*,^ID70[\,[I!KWND]& WU_5GQ9X8DP*,]T' MTGT@E-VGXL='1N_TV/O*%""/QA-A(^6 M6!HEH5PX'O(LQA$!V#(^B 0Q M?1)V5_2%D;B[C+V#5=$I4;5_V TLL5)F1F84DH/)_455CJW)W6 )=,0/!A%N,>8 M!"#>3H6,2.%!:N$SS>5H>'S7E4&TJ*G3,I[:DX#G35'"'U<;!VE)@V$^9(Q0 MJ]R=+JB$(+E1.!-*P37/1R/EL]U!6.13QV)''2?!P(6].0VH51&+NY;%?2"< M":&8] 0,5418 <3&: @PHSW'3X:-46Q^UXE!=.BITS&&PI- Y3@$3$%S_W96 M5,"6>;09C]Z3+,5A&7$U3EW7YG<>%U^,:F*YC<0+C754R"338[1FO^?#,$8F MW]P<0> I@7)>-ZTM_RXN^[(:'>7!*$-4!(S"8@!.Y)H$+0R-E&JGP]B8;'DP M#)()MS]'$O>%$>EFP.,$MO<[H])D,N,$/$Z$ F1.G.^Z-]IYX%Y+:]T8MW6^ ML#D,@PDW0W<6\(43W]U,+<_7=?6PR&+":J8#%LV>"YS76$:L48I(*96E4JM< MZA&2_[7=80!,N ?Z+"%?&((/J6A;J$[JS>:JNE](-4M#,X[A,F)]"#A]*4:T MU9+8D"NK@O76PP@D/&E\& X3[H ^7](79N)]71:^:(MJ]3L6/JFP9;>HQG^0 M!$!KG-8PCT[E@C@FG,*C XMC+#D>6QY&PX0[G,\4\X51.$_0<0Q8]O;W^[J' M2-);##XMI5 J=YH3UMWD%PKK')T'AVA[C[5.%O0H]>.W/1B&QH2[G".).RU$ M3IOF"M*7L5BJ8W!1$.Z[YP(\*&)L0/"UC!IX9"&.L1[]-S^&X3+AMN>H0K_T M)0;\%5XF;QEW%T5;PM+8C.I<:F'U_NW%UN61:9D5XG40'A V%4L:"#"\:,<:ML MR^BP![ FW,O<7<*)3 "O;_S:5BOH'Q.066Z5=)1DD5&\UC&+5ST-1.12<"%S M'N(8"]"G; \C8<(=RV<+.HE.Y>L-I!4"_5NJK]LU7NXN;76[=#R&+ B-J^@N M#",%T9YSHG0(TB+U+AOOAL>3+@S#8_*]RN?+.QHEKQ:/I#S##4=[]SNZE^X! M_:.]_P-02P$"% ,4 " #AB890:)D[\RX7 !PG $0 M@ $ ;&=N9"TR,#(P,#0P-BYH=&U02P$"% ,4 " #AB890>9T%$J," M +"@ $0 @ %=%P ;&=N9"TR,#(P,#0P-BYX&UL4$L! A0#% @ X8F&4"%&K] A @ D@8 M !4 ( !Y1L &QG;F0M,C R,# T,#9?9&5F+GAM;%!+ 0(4 M Q0 ( .&)AE"@\K&^@PH ,Y> 5 " 3D> !L9VYD M+3(P,C P-# V7VQA8BYX;6Q02P$"% ,4 " #AB890H _9;[,& !N,0 M%0 @ 'O* ;&=N9"TR,#(P,#0P-E]P&UL4$L%!@ 0 & 8 B@$ -4O $! end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}